Programs Last Minute List

This program has recently started, but it still may be possible to register if only the orientation class has been missed. Please calling us at 514-481-0317‬‬ to inquire, and fill out the form below to be added to our waiting list.
    You can select more than one option

This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning and role-play exercises. It is the first time a program of this kind has been offered in Canada.

Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.

Learning Objectives:

  • Discuss the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients.
  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings

Psychedelics 102: What are psychedelic harm reduction and integration and how can they occur in a clinical setting? This session focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.

Learning Objectives:

  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Describe the role of the therapist in an individual’s integration psychotherapy process

Fees:

Full program cost: $525

Limited number of student registration tickets available for $395

Continuing Education Information

This course has been approved by the OPQ for 12 hours of continuing education credits (recognition number: RA03123-19).

APA CE credits: $50 USD

CE credits for psychologists are provided by the Spiritual Competency Resource Center (SCRC) which is co-sponsoring this program. The Spiritual Competency Resource Center is approved by the American Psychological Association to sponsor continuing education for psychologists. The Spiritual Competency Resource Center maintains responsibility for this program and its content. SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California. The California Board of Behavioral Sciences accepts CE credits for LCSW, LPCC, LEP, and LMFT license renewal for programs offered by approved sponsors of CE by the American Psychological Association. LCSWs, MFTs, and other mental health professionals from states other than California need to check with their state licensing board as to whether or not they accept programs offered by approved sponsors of CE by the American Psychological Association. SCRC is approved by the California Board of Registered Nursing (BRN Provider CEP16887) for licensed nurses in California. For questions about CE, visit www.spiritualcompetency.com or contact David Lukoff, PhD at CE@spiritualcompetency.com.

Instructors


Ingmar Gorman, Ph.D.

Ingmar Gorman, Ph.D., is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program, where he leads groups, trainings, and works with individual clients. Dr. Gorman is also site co-principal Investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder. He is a NIH funded fellow at New York University and a board member of Horizons Media, Inc., a not for-profit educational charity and organizer of the Horizons Conference: Perspectives on Psychedelics.

Elizabeth Nielson, Ph.D.

Dr. Elizabeth Nielson is a psychologist with a holistic, compassionate, and integrative approach to psychotherapy. She specializes in treating addictive and mood disorders with a blend of of mindfulness-based interventions, dialectical behavior therapy, psychodynamic therapy, community reinforcement and family training (CRAFT), and principles of psychedelic-assisted therapy. Dr. Nielson is part of the Experimental Therapeutics Research Laboratory at NYU Langone School of Medicine where she is a therapist on the psilocybin-assisted treatment for alcohol dependence trial and on the MDMA-assisted psychotherapy for PTSD clinical trials.